Overview

A Study of Subcutaneous Lecanemab in Healthy Participants

Status:
Recruiting
Trial end date:
2021-12-07
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the absolute bioavailability and pharmacokinetic (PK) profile of a single dose of lecanemab when administered subcutaneously (SC) in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Eisai Inc.